Promethera Biosciences reshapes its leadership team

27-Jan-2015 - Belgium

Promethera Biosciences announces the resignation of Eric Halioua from his post as CEO of Promethera and all other functions within the company. He has decided to leave in order to concentrate on other projects.
 
As CEO of the company since it was founded in 2009, Eric Halioua was the driving force behind the operational and financial growth of Promethera Biosciences, working closely with Professor Etienne Sokal, the company’s scientific founder.
 
Eric Halioua was instrumental in setting up the staffing structure and in taking Promethera Hepastem into Phase I/II clinical trials for orphan diseases such as Crigler-Najjar syndrome and urea cycle disorder (UCD). The search for his successor has already begun. The chairman of the board of directors, Dr. John Tchelingerian, will assume the role of acting CEO during the transition phase.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances